These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25112308)

  • 1. A study of up to 12 years of follow-up of Friedreich ataxia utilising four measurement tools.
    Tai G; Corben LA; Gurrin L; Yiu EM; Churchyard A; Fahey M; Hoare B; Downie S; Delatycki MB
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):660-6. PubMed ID: 25112308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How is disease progress in Friedreich's ataxia best measured? A study of four rating scales.
    Fahey MC; Corben L; Collins V; Churchyard AJ; Delatycki MB
    J Neurol Neurosurg Psychiatry; 2007 Apr; 78(4):411-3. PubMed ID: 17056635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.
    Ribaï P; Pousset F; Tanguy ML; Rivaud-Pechoux S; Le Ber I; Gasparini F; Charles P; Béraud AS; Schmitt M; Koenig M; Mallet A; Brice A; Dürr A
    Arch Neurol; 2007 Apr; 64(4):558-64. PubMed ID: 17420319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FXN methylation predicts expression and clinical outcome in Friedreich ataxia.
    Evans-Galea MV; Carrodus N; Rowley SM; Corben LA; Tai G; Saffery R; Galati JC; Wong NC; Craig JM; Lynch DR; Regner SR; Brocht AF; Perlman SL; Bushara KO; Gomez CM; Wilmot GR; Li L; Varley E; Delatycki MB; Sarsero JP
    Ann Neurol; 2012 Apr; 71(4):487-97. PubMed ID: 22522441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does performance of the Friedreich Ataxia Functional Composite compare to rating scales?
    Tai G; Yiu EM; Delatycki MB; Corben LA
    J Neurol; 2017 Aug; 264(8):1768-1776. PubMed ID: 28695363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HFE p.C282Y heterozygosity is associated with earlier disease onset in Friedreich ataxia.
    Delatycki MB; Tai G; Corben L; Yiu EM; Evans-Galea MV; Stephenson SE; Gurrin L; Allen KJ; Lynch D; Lockhart PJ
    Mov Disord; 2014 Jun; 29(7):940-3. PubMed ID: 24390816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal study of the Friedreich Ataxia Impact Scale.
    Tai G; Yiu EM; Corben LA; Delatycki MB
    J Neurol Sci; 2015 May; 352(1-2):53-7. PubMed ID: 25840637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review.
    Jain P; Badgujar L; Spoorendonk J; Buesch K
    Ther Adv Rare Dis; 2022; 3():26330040221139872. PubMed ID: 37180421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring Friedreich ataxia: complementary features of examination and performance measures.
    Lynch DR; Farmer JM; Tsou AY; Perlman S; Subramony SH; Gomez CM; Ashizawa T; Wilmot GR; Wilson RB; Balcer LJ
    Neurology; 2006 Jun; 66(11):1711-6. PubMed ID: 16769945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exonic deletions of FXN and early-onset Friedreich ataxia.
    Anheim M; Mariani LL; Calvas P; Cheuret E; Zagnoli F; Odent S; Seguela C; Marelli C; Fritsch M; Delaunoy JP; Brice A; Dürr A; Koenig M
    Arch Neurol; 2012 Jul; 69(7):912-6. PubMed ID: 22409940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants.
    Regner SR; Wilcox NS; Friedman LS; Seyer LA; Schadt KA; Brigatti KW; Perlman S; Delatycki M; Wilmot GR; Gomez CM; Bushara KO; Mathews KD; Subramony SH; Ashizawa T; Ravina B; Brocht A; Farmer JM; Lynch DR
    J Child Neurol; 2012 Sep; 27(9):1152-8. PubMed ID: 22752494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three clinical rating scales in Friedreich ataxia (FRDA).
    Bürk K; Mälzig U; Wolf S; Heck S; Dimitriadis K; Schmitz-Hübsch T; Hering S; Lindig TM; Haug V; Timmann D; Degen I; Kruse B; Dörr JM; Ratzka S; Ivo A; Schöls L; Boesch S; Klockgether T; Klopstock T; Schulz JB
    Mov Disord; 2009 Sep; 24(12):1779-84. PubMed ID: 19562766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of spatiotemporal gait parameters in measuring disease severity in Friedreich ataxia.
    Milne SC; Hocking DR; Georgiou-Karistianis N; Murphy A; Delatycki MB; Corben LA
    Cerebellum; 2014 Dec; 13(6):677-88. PubMed ID: 25022367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data.
    Reetz K; Dogan I; Costa AS; Dafotakis M; Fedosov K; Giunti P; Parkinson MH; Sweeney MG; Mariotti C; Panzeri M; Nanetti L; Arpa J; Sanz-Gallego I; Durr A; Charles P; Boesch S; Nachbauer W; Klopstock T; Karin I; Depondt C; vom Hagen JM; Schöls L; Giordano IA; Klockgether T; Bürk K; Pandolfo M; Schulz JB
    Lancet Neurol; 2015 Feb; 14(2):174-82. PubMed ID: 25566998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study.
    Reetz K; Dogan I; Hilgers RD; Giunti P; Mariotti C; Durr A; Boesch S; Klopstock T; de Rivera FJR; Schöls L; Klockgether T; Bürk K; Rai M; Pandolfo M; Schulz JB;
    Lancet Neurol; 2016 Dec; 15(13):1346-1354. PubMed ID: 27839651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
    Pandolfo M; Arpa J; Delatycki MB; Le Quan Sang KH; Mariotti C; Munnich A; Sanz-Gallego I; Tai G; Tarnopolsky MA; Taroni F; Spino M; Tricta F
    Ann Neurol; 2014 Oct; 76(4):509-21. PubMed ID: 25112865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring Inhibition and Cognitive Flexibility in Friedreich Ataxia.
    Corben LA; Klopper F; Stagnitti M; Georgiou-Karistianis N; Bradshaw JL; Rance G; Delatycki MB
    Cerebellum; 2017 Aug; 16(4):757-763. PubMed ID: 28229372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales.
    Bürk K; Schulz SR; Schulz JB
    J Neurochem; 2013 Aug; 126 Suppl 1():118-24. PubMed ID: 23859347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.
    Friedman LS; Farmer JM; Perlman S; Wilmot G; Gomez CM; Bushara KO; Mathews KD; Subramony SH; Ashizawa T; Balcer LJ; Wilson RB; Lynch DR
    Mov Disord; 2010 Mar; 25(4):426-32. PubMed ID: 20063431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database.
    Metz G; Coppard N; Cooper JM; Delatycki MB; Dürr A; Di Prospero NA; Giunti P; Lynch DR; Schulz JB; Rummey C; Meier T
    Brain; 2013 Jan; 136(Pt 1):259-68. PubMed ID: 23365101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.